Associated Papers
Targeting the epigenome and tumor heterogeneity: advances in immunotherapy for chemoresistant metastatic colorectal cancer.
Cao Y et al.
Frontiers in Immunology, 2025
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › ERBB2_mutations
Roles of mitochondrial genetics in cancer metastasis.
Welch DR et al.
Trends in Cancer, 2022
Select a paper to view details